Skip to main content

Fat emulsion Pregnancy and Breastfeeding Warnings

Brand names: Clinolipid, Intralipid, Liposyn II, Liposyn III, Nutrilipid, Omegaven, SMOFlipid

Fat emulsion Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk.

AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned

Risk Summary: There are risks to the fetus associated with severe malnutrition during pregnancy.

Comments:
-There is no data on use in pregnant women to know this drugs risks, including the risk of fetal harm or reproductive effects.

Animal studies have not been conducted. There are no controlled data in human pregnancy. The background birth defect and miscarriage risk for the indicated population is not known. In the US general population, the estimated major birth defect risk is 2 to 4% and the miscarriage risk is 15 to 20%.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel.

See references

Fat emulsion Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comments:
-This drug is not expected to cause harm to a breastfed infant, however, here is no information regarding this drug on the presence in human milk, the effects on a breastfed infant, or effects on milk production.
-Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2018) "Product Information. Intralipid (fat emulsion, intravenous)." Baxter I.V. Systems Division
  3. (2018) "Product Information. Nutrilipid (fat emulsion, intravenous)." B. Braun Medical
  4. (2018) "Product Information. Smoflipid (fat emulsion, intravenous)." Fresenius Kabi USA, LLC
  5. (2023) "Product Information. Smoflipid (fat emulsion, intravenous)." Fresenius Kabi USA, LLC, SUPPL-10

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2018) "Product Information. Intralipid (fat emulsion, intravenous)." Baxter I.V. Systems Division
  3. (2018) "Product Information. Nutrilipid (fat emulsion, intravenous)." B. Braun Medical
  4. (2018) "Product Information. Smoflipid (fat emulsion, intravenous)." Fresenius Kabi USA, LLC
  5. (2023) "Product Information. Smoflipid (fat emulsion, intravenous)." Fresenius Kabi USA, LLC, SUPPL-10

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.